Abstract
Ten out of 20 (50%) 17-week-old female NOD/WEHI mice developed an acute form of autoimmune diabetes when injected with two large doses of cyclophosphamide (CY), given at 14-day intervals. If these mice were treated under a prophylactic regimen with 2.5 mg/kg body weight per day of the novel immunosuppressant deoxyspergualin (DSP) the onset of diabetes was completely prevented. Moreover, DSP-treated animals showed reduced signs of pancreatic insulitis, had lower percentages of splenic lymphoid cells (SLC) expressing IL-2 receptors and Ly-6C antigens on their surfaces, and these cells released lower amounts of interferon-gamma (IFN) when stimulated in vitro. These data, providing evidence for the capacity of DSP to protect NOD/WEHI mice from experimental autoimmune diabetes and to modulate histo-immunological pathogenic pathways, indicate DSP as a drug of potential interest in the treatment of human insulin-dependent diabetes mellitus.
| Original language | English |
|---|---|
| Pages (from-to) | 232-236 |
| Number of pages | 5 |
| Journal | Clinical and Experimental Immunology |
| Volume | 91 |
| Issue number | 2 |
| Publication status | Published - 1993 |
Fingerprint
Keywords
- autoimmune diabetes
- cyclophosphamide
- deoxyspergualin
- FK-506
- interferon-gamma
- NOD/ WEHI mouse
ASJC Scopus subject areas
- Immunology
Cite this
Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin. / Nicoletti, F.; Borghi, M. O.; Meroni, P. L.; Barcellini, W.; Fain, C.; Di Marco, R.; Menta, R.; Schorlemmer, H. U.; Bruno, G.; Magro, G.; Grasso, S.
In: Clinical and Experimental Immunology, Vol. 91, No. 2, 1993, p. 232-236.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin
AU - Nicoletti, F.
AU - Borghi, M. O.
AU - Meroni, P. L.
AU - Barcellini, W.
AU - Fain, C.
AU - Di Marco, R.
AU - Menta, R.
AU - Schorlemmer, H. U.
AU - Bruno, G.
AU - Magro, G.
AU - Grasso, S.
PY - 1993
Y1 - 1993
N2 - Ten out of 20 (50%) 17-week-old female NOD/WEHI mice developed an acute form of autoimmune diabetes when injected with two large doses of cyclophosphamide (CY), given at 14-day intervals. If these mice were treated under a prophylactic regimen with 2.5 mg/kg body weight per day of the novel immunosuppressant deoxyspergualin (DSP) the onset of diabetes was completely prevented. Moreover, DSP-treated animals showed reduced signs of pancreatic insulitis, had lower percentages of splenic lymphoid cells (SLC) expressing IL-2 receptors and Ly-6C antigens on their surfaces, and these cells released lower amounts of interferon-gamma (IFN) when stimulated in vitro. These data, providing evidence for the capacity of DSP to protect NOD/WEHI mice from experimental autoimmune diabetes and to modulate histo-immunological pathogenic pathways, indicate DSP as a drug of potential interest in the treatment of human insulin-dependent diabetes mellitus.
AB - Ten out of 20 (50%) 17-week-old female NOD/WEHI mice developed an acute form of autoimmune diabetes when injected with two large doses of cyclophosphamide (CY), given at 14-day intervals. If these mice were treated under a prophylactic regimen with 2.5 mg/kg body weight per day of the novel immunosuppressant deoxyspergualin (DSP) the onset of diabetes was completely prevented. Moreover, DSP-treated animals showed reduced signs of pancreatic insulitis, had lower percentages of splenic lymphoid cells (SLC) expressing IL-2 receptors and Ly-6C antigens on their surfaces, and these cells released lower amounts of interferon-gamma (IFN) when stimulated in vitro. These data, providing evidence for the capacity of DSP to protect NOD/WEHI mice from experimental autoimmune diabetes and to modulate histo-immunological pathogenic pathways, indicate DSP as a drug of potential interest in the treatment of human insulin-dependent diabetes mellitus.
KW - autoimmune diabetes
KW - cyclophosphamide
KW - deoxyspergualin
KW - FK-506
KW - interferon-gamma
KW - NOD/ WEHI mouse
UR - http://www.scopus.com/inward/record.url?scp=0027400806&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027400806&partnerID=8YFLogxK
M3 - Article
C2 - 8428390
AN - SCOPUS:0027400806
VL - 91
SP - 232
EP - 236
JO - Clinical and Experimental Immunology
JF - Clinical and Experimental Immunology
SN - 0009-9104
IS - 2
ER -